WOONSOCKET, R.I., June 14 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).
In an earlier Phase IIa study, MCT-125 was tested on 138 patients suffering from PMSF. MCT-125 was shown to be effective within 4 weeks of administration, was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type (primary progressive, secondary progressive and relapsing-remitting).
MCT-125 is a fixed dose, orally delivered, combination therapeutic acting on noradrenergic neurons and tyrosine hydroxylase to block the reuptake of noradrenaline with little or no direct action on serotoninergic neurons. The synthesis of noradrenaline in noradrenergic neurons is tightly regulated by tyrosine hydroxylase acting as the key rate-limiting step. MCT-125 is thought to lead to the greater availability of noradrenaline in the central nervous system resulting in a decrease in fatigue levels.
Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath insulating neurons in the brain and spinal cord. Approximately 350,000 individuals have been diagnosed with MS in the United States, and m